FDA Approval Alert: The Need-to-Know | Polatuzumab Vedotin/R-CHP in Previously Untreated DLBCL

In April 2023, the FDA approved polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as a treatment for patients with previously untreated diffuse large B-cell lymphoma.

Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone as treatment following the FDA’s approval of the regimen.
FDA Approves Polatuzumab Vedotin/R-CHP Combo in Previously Untreated DLBCL
Article
Apr 19, 2023 8:34 PM
Patients with previously untreated diffuse large B-cell lymphoma can now receive polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone following the FDA’s approval of the regimen.
Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert Says
Video
Apr 19, 2023 8:26 PM
Polatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.